바이오의약품 계약 서비스 시장 : 예측(-2032년) - 서비스 유형별, 연구 서비스별, 기술별, 용도별, 최종사용자별, 지역별

According to Stratistics MRC, the Global Biopharma Contract Services Market is accounted for $27.01 billion in 2025 and is expected to reach $51.97 billion by 2032 growing at a CAGR of 9.8% during the forecast period. Biopharma Contract Services refer to specialized outsourcing solutions provided to biotechnology and pharmaceutical companies to support the research, development, and commercialization of therapeutic products. These services encompass a wide spectrum, including contract research (CRO), contract manufacturing (CMO), clinical trial management, regulatory compliance, analytical testing, and quality assurance. By leveraging external expertise and infrastructure, biopharma companies can accelerate drug development timelines, reduce operational costs, and mitigate risk while maintaining compliance with stringent regulatory standards. These partnerships enable scalable, flexible, and innovative solutions, fostering efficiency and precision across preclinical research, clinical trials, manufacturing, and post-market support within the global biopharmaceutical ecosystem.

Market Dynamics:

Driver:

Rising Demand for Biologics & Biosimilars

The growing demand for biologics and biosimilars is a primary driver of the Biopharma Contract Services Market. Increasing prevalence of chronic and complex diseases, coupled with a shift toward targeted therapies, has intensified the need for outsourced development and manufacturing solutions. Contract services enable biopharma companies to accelerate biologics and biosimilar production, optimize clinical trial efficiency, and ensure regulatory compliance. This rising demand supports market expansion by facilitating access to advanced infrastructure, specialized expertise, and scalable solutions for innovative therapeutics.

Restraint:

High Capital & Operational Costs

High capital investment and operational costs remain significant restraints for the Market. Establishing advanced facilities, maintaining regulatory compliance, and implementing sophisticated technologies require substantial financial resources. Smaller biotechnology firms may face challenges accessing comprehensive contract services due to budget constraints. Additionally, the continuous need for skilled personnel, equipment maintenance, and quality assurance increases operational burdens. These financial and logistical pressures can slow adoption and limit market growth.

Opportunity:

Advancements in technology

Technological advancements present significant growth opportunities in the market. Innovations in automation, high-throughput screening, molecular diagnostics, and advanced analytics enable faster, more accurate drug development. By adopting these technologies, contract service providers can enhance efficiency, reduce errors, and offer scalable solutions for complex biologics, biosimilars, and personalized medicines. Companies that leverage cutting-edge tools gain competitive advantage and expand service offerings, positioning the market for sustained growth across preclinical, clinical, and commercial phases.

Threat:

Supply Chain Vulnerabilities

Supply chain vulnerabilities pose a notable threat to the market. Dependence on global suppliers for raw materials, specialized equipment, and advanced reagents exposes the sector to disruptions from geopolitical tensions, regulatory changes, or logistical challenges. Interruptions in production and delays in clinical trial materials can impact timelines, increase costs, and compromise quality standards. Such vulnerabilities necessitate robust risk management, strategic sourcing, and contingency planning to maintain service continuity and protect market growth in a highly regulated, time-sensitive industry.

Covid-19 Impact:

The COVID-19 pandemic significantly influenced the market. While it disrupted supply chains, clinical trials, and manufacturing operations, it also accelerated outsourcing adoption as companies sought flexible, scalable solutions to maintain R&D productivity. Contract service providers played a key role in supporting vaccine development, rapid testing, and therapeutic innovations. Pandemic-driven digital transformation and adoption of remote monitoring, decentralized trials, and advanced analytics further strengthened the market.

The clinical trials segment is expected to be the largest during the forecast period

The clinical trials segment is expected to account for the largest market share during the forecast period, due to increasing complexity and volume of drug development programs, particularly for biologics and biosimilars. Outsourcing clinical trial management enables biopharma companies to access specialized expertise, enhance patient recruitment, ensure regulatory compliance, and streamline operational efficiency. As a result, clinical trial services remain critical for accelerating time-to-market while maintaining high standards of data quality and safety.

The pharmaceutical companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the pharmaceutical companies segment is predicted to witness the highest growth rate, due to rising outsourcing adoption to optimize R&D productivity, reduce costs, and mitigate risks associated with complex drug development. By partnering with biopharma contract service providers, pharmaceutical firms can leverage advanced analytical technologies, regulatory support, and scalable manufacturing capabilities. Increasing demand for innovative therapeutics, biosimilars, and personalized medicine further positions pharmaceutical companies as key drivers of market expansion globally.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to growing biopharmaceutical industry, expanding clinical research infrastructure, cost-effective outsourcing solutions, and supportive government initiatives. Increasing biologics and biosimilar production, coupled with the region's skilled workforce and favorable regulatory reforms, enhances its appeal as a strategic hub for biopharma contract services. Strong partnerships between global and local players further reinforce regional market dominance.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to technological innovation in biopharma outsourcing. The region benefits from a high concentration of leading pharmaceutical and biotechnology companies seeking specialized contract services to accelerate clinical trials, regulatory compliance, and manufacturing. Increasing demand for personalized medicine, biosimilars, and biologics, alongside strong regulatory frameworks, positions North America as a rapidly growing market for scalable, high-quality biopharma contract solutions.

Key players in the market

Some of the key players in Biopharma Contract Services Market include Thermo Fisher Scientific Inc., KBI Biopharma, Lonza Group AG, Cambrex Corporation, WuXi AppTec, Charles River Laboratories, WuXi Biologics, AbbVie Contract Manufacturing, Catalent Inc., FUJIFILM Diosynth Biotechnologies, Samsung Biologics, Boehringer Ingelheim BioXcellence, Recipharm AB, Rentschler Biopharma SE and AGC Biologics.

Key Developments:

In January 2026, TetraScience has entered a strategic collaboration with Thermo Fisher Scientific to accelerate scientific data transformation and AI enablement across biopharma laboratories. By integrating Thermo Fisher's instruments and informatics with TetraScience's AI-native data platform and intelligent workflows, the partnership aims to standardize fragmented lab data and power scalable, high-value AI use cases that enhance reproducibility, throughput, and decision-making in R&D and manufacturing.

In October 2025, Thermo Fisher Scientific's PPD clinical research arm has forged a new R&D partnership with AstraZeneca's BioVentureHub in Gothenburg, Sweden, co-locating teams to collaborate on projects in chromatography, molecular genomics and proteomics, boosting innovation and strengthening the life science ecosystem.

Service Types Covered:

• Contract Research Organization (CRO) Services
• Contract Manufacturing Organization (CMO) Services
• Contract Development and Manufacturing Organization (CDMO) Services

Research Services Covered:

• Oncology
• Inflammation & Immunology
• Vaccines
• Cardiology
• Other Research Services

Technologies Covered:

• Biologics
• Gene Therapy
• Small Molecules
• Cell Therapy

Applications Covered:

• Clinical Trials
• Drug Development
• Drug Discovery
• Other Applications

End Users Covered:

• Pharmaceutical Companies
• Biotechnology Companies
• Research Institutes & Academic Centers

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Technology Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Biopharma Contract Services Market, By Service Type

• 5.1 Introduction
• 5.2 Contract Research Organization (CRO) Services
  • 5.2.1 Preclinical Services
  • 5.2.2 Regulatory Affairs Services
  • 5.2.3 Clinical Trial Services
• 5.3 Contract Manufacturing Organization (CMO) Services
  • 5.3.1 Biologic Manufacturing
  • 5.3.2 Cell and Gene Therapy Manufacturing
  • 5.3.3 Small Molecule Manufacturing
• 5.4 Contract Development and Manufacturing Organization (CDMO) Services
  • 5.4.1 Drug Development Services
  • 5.4.2 Analytical & Quality Testing
  • 5.4.3 Formulation Development

6 Global Biopharma Contract Services Market, By Research Service

• 6.1 Introduction
• 6.2 Oncology
• 6.3 Inflammation & Immunology
• 6.4 Vaccines
• 6.5 Cardiology
• 6.6 Other Research Services

7 Global Biopharma Contract Services Market, By Technology

• 7.1 Introduction
• 7.2 Biologics
• 7.3 Gene Therapy
• 7.4 Small Molecules
• 7.5 Cell Therapy

8 Global Biopharma Contract Services Market, By Application

• 8.1 Introduction
• 8.2 Clinical Trials
• 8.3 Drug Development
• 8.4 Drug Discovery
• 8.5 Other Applications

9 Global Biopharma Contract Services Market, By End User

• 9.1 Introduction
• 9.2 Pharmaceutical Companies
• 9.3 Biotechnology Companies
• 9.4 Research Institutes & Academic Centers

10 Global Biopharma Contract Services Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Thermo Fisher Scientific Inc.
• 12.2 KBI Biopharma
• 12.3 Lonza Group AG
• 12.4 Cambrex Corporation
• 12.5 WuXi AppTec
• 12.6 Charles River Laboratories
• 12.7 WuXi Biologics
• 12.8 AbbVie Contract Manufacturing
• 12.9 Catalent Inc.
• 12.10 FUJIFILM Diosynth Biotechnologies
• 12.11 Samsung Biologics
• 12.12 Boehringer Ingelheim BioXcellence
• 12.13 Recipharm AB
• 12.14 Rentschler Biopharma SE
• 12.15 AGC Biologics